Endobronchial photodynamic therapy: Comparison of mTHPC and polyethylene glycol-derived mTHPC on human tumor xenografts and tumor-free bronchi of minipigs

Lasers in Surgery and Medicine

Volumn 23, Issue 1, 1998, Pages 25-32

  Ris, Hans Beat ^a   Im Hof, Vinzenz ^a   Stewart, Charles M ^b   Mettler, D ^a   Altermatt, Hans Jörg ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Scotia Pharmaceuticals   (United Kingdom)

Author keywords

Adenocarcinoma; M tetrahydroxyphenylchlorin; Nude mice; Squamous cell carcinoma

Indexed keywords

3 TETRAHYDROXYPHENYLCHLORIN; MACROGOL; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER TRANSPLANTATION; DOSE RESPONSE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MORPHOMETRICS; MOUSE; NONHUMAN; NUDE MOUSE; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL;

EID: 2642646202     PISSN: 01968092     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9101(1998)23:1<25::AID-LSM4>3.0.CO;2-Y     Document Type: Article

References (36)

1. Smith SG, Bedwell J, MacRobert AJ, Griffiths MH, Bown SG, Hetzel MR. Experimental studies to assess the potential of photodynamic therapy for the treatment of bronchial carcinomas. Thorax 1993; 48:474-480.
2. Monnier Ph, Fontolliet Ch, Wagnières G, Braichotte D, Van den Bergh H. Further appraisal of PDI and PDT of early squamous cell carcinomas of the pharynx, oesophagus and bronchi. In: Spinelli P, Dal Fante M, Marchesini R, eds. "Photodynamic Therapy and Biomedical Lasers." Amsterdam: Excerpta Medica, 1992, pp 7-14.
3. Furuse K, Fukuoka M, Kato H, Horai T, Kubota K, Kodama N, Kusunoki Y, Takifuji N, Okunaka T, Konaka C. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancers. Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol 1993; 11:1844-1845.
4. Monnier Ph, Savary M, Fontolliet Ch. Photodetection and photodynamic therapy of early squamous cell carcinomas of the pharynx, oesophagus and tracheo-bronchial tree. Lasers Medical Sci 1990; 5:149-169.
5. Pelton JJ, Kovalyshin MJ, Keller SM. Intrathoracic organ injury associated with photodynamic therapy. J Thoracic Cardiovasc Surg 1992; 103:1218-1223.
6. Tochner ZA, Pass HI, Smith PD, De Laney TF, Sprague M, DeLuca AM, Harrington F, Thomas GF, Terril R, Bacher JD. Intrathoracic photodynamic therapy: a canine normal tissue tolerance study and early clinical experience. Lasers Surg Med 1994; 14:118-123.
7. DeLaney TF, Sindelar WF, Thomas GF, DeLuca AM, Taubenberger JK. Tolerance of small bowel anastomoses in rabbits to photodynamic therapy with dihematopor-phyrin ethers and 630 nm red light. Lasers Surg Med 1993; 13:664-671.
8. Stewart FA, Oussoren Y. Functional and histological bladder damage in mice after photodynamic therapy: the influence of sensitizer dose and time of administration. Br J Cancer 1993; 68:673-677.
9. Pass HI, De Laney TF, Tochner Z, Smith PE, Temeck BK, Progebniak HW, Kranda KC, Russo A, Friauf WS, Cole JW, Mitchell JB, Thomas G. Intrapleural photodynamic therapy: results of a phase I trial. Ann Surg Oncol 1994; 1:28-37.
10. Takita H, Mang TS, Loeven GM, Antkowiak JG, Raghavan D, Grajek JR, Dougherty TJ. Operation and intra-cavitary photodynamic therapy for malignant mesothelioma: a phase II study. Ann Thorac Surg 1994; 58:995-998.
11. Ash DV, Brown SB. New drugs and future developments in photodynamic therapy. Eur J Cancer 1993; 29:1781-1783.
12. Ris HB, Altermatt HJ, Inderbitzi R, Hess R, Nachbur B, Stewart JCM, Bonnett R, Berenbaum MC, Althaus U. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer 1991; 64:1116-1120.
13. Ris HB, Altermatt HJ, Nachbur B, Stewart JCM, Wang Q, Lim CK, Bonnett R, Althaus U. Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer 1993; 53:141-146.
14. Ris HB, Altermatt HJ, Stewart JCM, Schaffner T, Wang Q, Lim CK, Bonnett R, Althaus U. Photodynamic therapy with m-tetrahydroxyphenylchlorin in vivo: optimization of the therapeutic ratio. Int J Cancer 1993; 55:245-249.
15. Burnham NL. Polymers for delivering peptides and proteins. Am J Hosp Pharm 1994; 51:210-218.
16. Allemann E, Brasseur N, Benrezzak O, Rousseau J, Kudrevich SV, Boyle RW, Leroux JC, Gurny R, Van Lier JE. PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to emt-6 mouse mammary tumours. J Pharm Pharmacol 1995; 47: 382-387.
17. Altermatt HJ, Gebbers JO, Laissue JA. Heavy water delays growth of human carcinoma in nude mice. Cancer 1988; 62:462-466.
18. Bonnett R, Berenbaum MC. Porphyrins as sensitizers. In: Ciba Foundation Symposium 146, "Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use." Chichester: Wiley & Sons, 1989, pp 40-53.
19. Hayata Y, Kato H, Konaka C. Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer. Chest 1982; 81:269-277.
20. Hayata Y, Kato H, Konaka C. Photodynamic therapy in early stage lung cancer. Lung Cancer 1993; 9:287-294.
21. Kato H, Konaka C, Ono J. Preoperative laser photodynamic therapy in combination with operation in lung cancer. J Thorac Cardiovasc Surg 1985; 90:420-429.
22. Lam S. Photodynamic therapy of lung cancer. Semin Oncol 1994; 21:15-19.
23. McCaughan JS. Photodynamic therapy versus NdYAG laser treatment of endobronchial or esophageal malignancies. In: Spinelli P, Dal Fante M, Marchesini R, eds. "Photodynamic Therapy and Biomedical Lasers." Amsterdam: Excerpta Medica, 1992, pp 23-36.
24. Dougherty TJ, Cooper MT, Mang TS. Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg Med 1990; 10:485-488.
25. Berenbaum MC, Bonnett R, Scourides PA. In vivo biological activity of the components of haematoporphyrin derivative. Br J Cancer 1982; 45:571-581.
26. Levy JG. Photosensitizers in photodynamic therapy. Semin Oncol 1994; 21:4-10.
27. Van der Veen N, Van Leengoed HL, Star WM. In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations. Br J Cancer 1994; 70: 867-872.
28. Van Geel I, Oppelaar H, Oussoren YG, Van der Valk MA, Stewart FA. Photosensitizing efficacy of mTHPC-PDT compared to Photofrin-PDT in the RIF1 mouse tumor and normal skin. Int J Cancer 1995; 60:388-394.
29. Gibson SL, Foster TH, Feins RH, Raubertas RF, Fallon MA, Hilf R. Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice. Br J Cancer 1994; 69:473-481.
30. Lofgren LA, Ronn AM, Abramson AL, Shikowitz MJ, Nouri M, Lee CJ, Batti J, Steinberg BM. Photodynamic therapy using m-tetra(hydroxyphenyl)chlorin: an animal model. Arch Otolaryngol Head Neck Surg 1994; 120: 1355-1362.
31. Wilson BC, Patterson MS. The determination of light fluence distribution in photodynamic therapy. In: Kessel D, ed. "Photodynamic Therapy of Neoplastic Disease," vol. 1. Boca Raton: CRC Press, 1990, pp 129-146.
32. Ma L, Moan J, Berg K. Evaluation of a new photosensitizer, meso-tetra-hydroxyphenylchlorin for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitizers. Int J Cancer 1994; 57:883-888.
33. Ris HB, Altermatt HJ, Nachbur B, Stewart JCM, Wang Q, Lim CK, Bonnett R, Althaus U. Intraoperative photodynamic therapy with mTHPC for chest malignancies. Lasers Surg Med 1996; 18:39-45.
34. Veenhuizen RB, Ruevekamp-Helmers MC, Helmerhorst TJ, Kenemans P, Mooi WJ, Marijnissen JP, Stewart FA. Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and mTHPC. Int J Cancer 1994;59:830-836.
35. Abramson AL, Lofgren LA, Ronn AM, Nouri M, Steinberg BM. Treatment effects of meta-tetrahydroxyphenylchlorin on the larynx. In: Horrobin DF, ed. "New Approaches to Cancer Treatment." London: Churchill, 1994, pp 142-147.
36. Gibson SL, Foster TH, Feins RH, Raubertas RF, Fallon MA, Hilf R. Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice. Br J Cancer 1994; 69:473-481.